TABLE 1.
Atazanavir parameter estimates and standard errors obtained from the final population pharmacokinetic modela
| Parameter | Estimate (% RSE) |
Bootstrapped median (95% CI) in the final model | |
|---|---|---|---|
| Basic model | Final model | ||
| CL/F (liters/h) | 18.4 (12.4) | 19.7 (6.1) | 19.4 (15.9, 22.9) |
| V/F (liters) | 122 (17.1) | 136 (16.5) | 133 (105.7, 158.3) |
| Ka (h−1) | 2.3 (37.1) | 2.3 (3.9) | 2.7 (0.3, 11) |
| Lag time (h) | 1.3 (0.1) | 1.3 (0.005) | 1.5 (0.6, 1.6) |
| IIV CL/F (%) | 25.3 (39.3) | 21.5 (26.1) | 22 (15, 30) |
| Residual error: proportional % | 36.5 (11.0) | 38.5 (8.6) | 39.1 (25, 44) |
| Factor associated with C/T on ATV CL/F | −0.18 (63) | −0.20 (−1.7, 2.2) | |
| Factor associated with T/T on ATV CL/F | 3.4 (4.7) | 3.1 (0.3, 6.1) | |
| Fdiurnal | 1.34 (10) | 1.30 (1.0, 1.6) | |
a
Abbreviations: RSE, relative standard error; CL/F, apparent oral clearance; V/F, apparent volume of distribution; Ka, absorption rate constant; IIV, interindividual variability; Fdiurnal, bioavailability for evening dose; CI, confidence interval. RSE was defined as (SEestimate/estimate) × 100.